Coral Laboratories Ltd Share Price

Coral Labs.
Small Cap | Pharmaceuticals
₹ 448.9 7.65 (1.73%)
Last updated: 16-Jan-2026 , 16:01:36

Coral Laboratories Ltd Live Price Chart

Low: ₹433 High: 454

Coral Laboratories Ltd Technicals

Current Price
₹ 448.9 7.65 (1.73%)
EMASMA
20 Day ₹ 450.404
50 Day ₹ 466.784
100 Day ₹ 495.266
200 Day ₹ 542.897
20 Day ₹ 451.590
50 Day ₹ 470.023
100 Day ₹ 487.044
200 Day ₹ 558.103

Coral Laboratories Ltd Performance

Previous Close ₹ 441.25
High ₹ 454
Volume 486
52W Range ₹ 419 - ₹ 850.9
Open ₹ 443.05
Low ₹ 433
Market Cap 175 Cr

Coral Laboratories Ltd Fundamentals

ROCE 10.974
P/E Ratio 9.180
P/B Ratio 0.750
Industry P/E 0.750
Debt to Equity 39.228
ROE 8.145
EPS 48.620
Dividend Yield 0.000
Book Value 596.885
Face Value 10.000

Coral Laboratories Ltd Financials

Particulars Y202503 Y202403 Y202303 Y202203 Y202103
Total Revenue 124.1139 90.2928 85.0135 80.4245 100.3373
Total Expenses 90.8741 69.3973 76.8255 69.5282 82.7435
Profit After Tax 24.1556 15.789 6.4454 9.0457 13.5546

Coral Laboratories Ltd Shareholding Pattern

Promoter Holdings 71.511 %
FIIs 0.000 %
DIIs 0.000 %
MutualFund 0.000 %
Retail 20.522 %
Others - 7.967 %

About Coral Laboratories Ltd

History of Coral Laboratories Ltd

Coral Laboratories Limited (CLL) was established in February, 1997. Carol Labs are into manufacturing of Generic Branded, Nutraceuticals, OTC and Herbal Medicines. The Company produces various pharmaceutical formulations in 3 different locations all over India. It has plants at Daman and Dehradun . The Company was promoted by Navin B Doshi of the DWD group. To manufacture pharmaceutical formulations like tablets, capsules, liquid and topical preparation, the Company went into public issue in March 94 at a total cost of Rs.2.5 crores. It setup an additional ultra-modern manufacturing unit at Daman and the said Unit started the commercial production during March 2004. It started the commercial production at Dehradun Plant in September, 2006. ...

Similar Stocks

Company 52 Week Market Price P/E Ratio
Amrutanjan Health Care Ltd ₹ 544.1 - ₹ 790.95 610 31.11
Bliss GVS Pharma Ltd ₹ 108.12 - ₹ 195.8 172 23.23
Biofil Chemicals & Pharmaceuticals Ltd ₹ 30.35 - ₹ 62.88 32.6 18.52
Marksans Pharma Ltd ₹ 162 - ₹ 276.4 170.4 32.38
Syncom Formulations (India) Ltd ₹ 12.8 - ₹ 23.49 13.05 19.36

FAQs on Coral Laboratories Ltd

1. Can I buy Coral Laboratories Ltd from PL Capital? ›

Yes, you can invest in Coral Laboratories Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Coral Laboratories Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Coral Laboratories Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.

2. Does Coral Laboratories Ltd pay dividends? ›

Coral Laboratories Ltd does not currently pay dividends. Investors in this case primarily benefit from capital appreciation, where the value of the stock may rise over time depending on business growth and market conditions.

3. What is the current share price of Coral Laboratories Ltd ? ›

As of 16-01-2026 the share price for Coral Laboratories Ltd. is 446.15 on the NSE (Note: Prices are dynamic and update frequently during market hours).

4. What is the 52-week high and low of Coral Laboratories Ltd ? ›

The 52-week high and low of Coral Laboratories Ltd share price is ₹ 419 - ₹ 850.9 as of 16-01-2026 .
PL Ringside View

Our fireside chat series where industry experts and top management share valuable insights for our clients

Youtube

Mark Mobius on India’s Growth, Global Markets, and Investment Opportunities

Youtube

₹100 cr net profit in 7-12 months | Anjali Nashier, Revolt Motors

Youtube

India's Path to Energy Security | Dr. Praveer Sinha, MD & CEO, Tata Power

  • PL Capital Logo

  • Regd. Office : 3rd Floor, Sadhana House,
    570, P. B. Marg, Behind Mahindra Tower,
    Worli, Mumbai - 400 018, India

    View on Google Maps

  • Tel. : 02266322222

    Call us

Prabhudas Lilladher Private Limited | CIN: U67190MH1983PTC029670 | Registered Office Address: 3rd Floor, Sadhana House, 570, P.B. Marg, Worli, Mumbai – 400018, Maharashtra, India | SEBI Registration Details: Stock Broking: INZ000196637 [Membership Codes: NSE – 05977; BSE – 564; MCX – 40690] | Depository Participant: IN-DP-439-2019 [DP Codes: CDSL – 12011300; NSDL – IN303868 | Portfolio Management: INP000009001| Research Analyst: INZ000000271 | Investment Advisors: INA000018267 [BSEASL Membership Code: BASL2042] | AMFI ARN: 3276 | Compliance Officer: Mrs. Snehal Kathrani; Tel: 02266322420; email: co@plindia.com | For any Grievance/ Dispute: Stock Broking; email: grievance-br@plindia.com; Tel: 02266322366; Depository Participant; email: grievance-dp@plindia.com; Tel: 02266322452; Portfolio Management; email: grievance-pms@plindia.com; Tel: 02266322350.

To register your grievance on SCORES log onto: https://scores.gov.in/scores/Welcome.html. Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, Email ID

To register your grievance on Smart ODR Portal log onto: Online Dispute Resolution Portal (ODR Portal).

Standard Disclaimers: (a) Investment in securities market are subject to market risks, read all the related documents carefully before investing. (b) Brokerage will not exceed the SEBI prescribed limits. (c) Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The brand name and Logo ‘PL Capital’ are the registered trademarks of Prabhudas Lilladher Advisory Services Private Limited which is the holding company of Prabhudas Lilladher Group of Companies .

Prabhudas Lilladher Private Limited is not associated with any unregulated platform which claims performance/return for algorithmic strategy for trading. Trading with unregulated platforms for algorithmic strategy shall be at your own risk and Prabhudas Lilladher Private Limited or its affiliates shall not be liable for the same.

Risk Disclosure on Derivatives: (a) 9 out of 10 individual traders in equity futures and options segment, incurred net losses. (b) On an average, loss makers registered net trading loss close to ₹ 50,000 (c) Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs. (d) Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source